AGP Executive Report
Last update: 11 hours agoFDA Approvals: The FDA cleared AstraZeneca and Daiichi Sankyo’s Datroway (datopotamab deruxtecan) for adults with metastatic triple-negative breast cancer who can’t take PD-1/PD-L1 inhibitors, adding a new first-line option backed by Phase 3 survival and progression-free results. Infectious Disease Watch: In DR Congo, Ebola fears are rising as the outbreak reaches nearly 750 suspected cases and 177 deaths, with the WHO upgrading risk to “very high” and noting the Bundibugyo strain has no approved targeted tools. Policy & Access: HHS is launching AI-powered audit enforcement to flag persistent fraud, waste, and abuse across federal programs. Healthcare Delivery: Glasgow’s Queen Elizabeth University Hospital helipad hit 3,000+ emergency helicopter landings since 2015, underscoring the role of rapid transfers for critically ill patients. Industry Moves: Biogen completed its acquisition of Apellis, bringing SYFOVRE (pegcetacoplan) under a new complement-focused umbrella. Local Tensions: Oklahoma’s family-backed epilepsy bill was vetoed by Gov. Stitt, keeping coverage expansion for SUDEP-prevention therapies off the books.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result.
Perspectify News
![<![CDATA[FDA Accepts NDA for Asundexian, Dysport Noninferior Botox in Safety Profile, gMG Bridging the Gaps Discussion]]>](https://cdn.sanity.io/images/0vv8moc6/neurolive/220831d7b974bb27bb9797e31d5ef21f2d8e0c01-1920x1080.jpg)
